Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/22
Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/22
Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10GlobeNewsWire • 11/03/22
Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022GlobeNewsWire • 10/06/22
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2022 Results Earnings Call TranscriptSeeking Alpha • 08/11/22
Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/10/22
Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10GlobeNewsWire • 08/03/22
Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 07/19/22
Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension StudyGlobeNewsWire • 06/27/22
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual ConferenceGlobeNewsWire • 06/17/22
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/18/22
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/10/22
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10GlobeNewsWire • 05/03/22
Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease SummitGlobeNewsWire • 03/29/22
Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 PatientsGlobeNewsWire • 03/28/22
The Lancet Publishes Positive Results from Capricor Therapeutics' Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular DystrophyGlobeNewsWire • 03/11/22
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/10/22
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/10/22
Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10GlobeNewsWire • 03/03/22
Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical DevelopmentGlobeNewsWire • 03/02/22
Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in USPRNewsWire • 01/25/22